NCT04548440View on ClinicalTrials.gov

Efficacy and Safety of Preoperative Sintilimab Plus Nab-paclitaxel and Cisplatin in BR-ESCC Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

August 31, 2020

Primary Completion Date

December 31, 2022

Study Completion Date

December 31, 2022

Conditions
Esophageal Squamous Cell Carcinoma
Interventions
DRUG

Sintilimab

Route of administration: Intravenous

DRUG

Nab paclitaxel

Route of administration: Intravenously over 30min

DRUG

Cisplatin

Route of administration: Intravenous

Trial Locations (1)

510060

Sun Yat-sen University Cancer Center, Guangzhou

Sponsors
All Listed Sponsors
collaborator

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

collaborator

CSPC Pharmaceutical Group Limited

INDUSTRY

lead

Sun Yat-sen University

OTHER

NCT04548440 - Efficacy and Safety of Preoperative Sintilimab Plus Nab-paclitaxel and Cisplatin in BR-ESCC Patients | Biotech Hunter | Biotech Hunter